发明名称 |
Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
摘要 |
A compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and/or heart failure. ARB includes S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na+. The compound includes trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate. |
申请公布号 |
US8877938(B2) |
申请公布日期 |
2014.11.04 |
申请号 |
US200611722360 |
申请日期 |
2006.11.08 |
申请人 |
Novartis Pharmaceuticals Corporation |
发明人 |
Feng Lili;Godtfredsen Sven Erik;Hu Bin;Liu Yugang;Karpinski Piotr;Sutton Paul Allen;Prashad Mahavir;Girgis Michael J.;Blacklock Thomas J. |
分类号 |
C07D257/04;C07C233/47;A61K31/41;A61K31/4422;A61K31/5415 |
主分类号 |
C07D257/04 |
代理机构 |
|
代理人 |
Mulkeen Matthew |
主权项 |
1. Trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate in crystalline form. |
地址 |
East Hanover NJ US |